Anna Azvolinsky, PhD

Anna Azvolinsky, PhD

Freelance Science Writer and Cancer Network Contributor.

Follow Her on Twitter

Posts by Author

Subpopulation of Breast Cancer Patients Most Likely to Respond to Palbociclib

This slide show features some of the highlights from the 105th Annual Meeting of the American Association for Cancer Research (AACR), including a breast cancer trial of .

Patients with localized prostate cancer treated with primary androgen deprivation therapy (ADT) without radiation therapy or surgery derived no survival benefit, according to the results of a large study.

A new pilot study demonstrates the ability of a blood-based test to detect metastatic breast cancer recurrence with high sensitivity and specificity.

This slide show includes highlights from the 2014 Society of Gynecologic Oncology annual meeting, including one study showing bariatric surgery could lower the risk of uterine cancer, and another that found a PARP inhibitor active in BRCA-positive ovarian cancer.

Loss of the tumor suppressor PTEN was found to be a frequent mechanism of resistance to treatment with the PI3K-alpha inhibitor BYL719 in women with breast cancer.

A high body mass index prior to a colorectal cancer diagnosis is linked to a higher risk of death, even when the patient’s tumor type is generally associated with a better prognosis.

Researchers have identified a potential biomarker that may confer inherent resistance to enzalutamide for patients with castration-resistant prostate cancer.

Two early trials studying CDK inhibitors in metastatic breast cancer have shown impressive activity in HR-positive disease, according to data presented at the AACR annual meeting.

Advanced melanoma patients treated with the anti–PD-1 inhibitor MK-3475 with tumors that expressed PD-L1 had higher survival rates and more robust immune responses compared with patients with tumors that did not express PD-L1.

In a phase I trial, non–small-cell lung cancer (NSCLC) patients with tumors that expressed PD-L1 had significantly better outcomes with MK-3475 therapy compared with patients with PD-L1–negative tumors.


Please Wait 20 seconds or click here to close